Zevra Therapeutics Inc
KMPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$200.47M
Close$
$34.03
485.7% upside
Current Fair Value
485.7% upsideUndervalued by 485.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $200.47 Million |
|---|---|
| Enterprise Value | $78.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.4 |
| Beta | 2.16 |
| Outstanding Shares | 59,155,970 |
Return
| Return on Equity | 26.77% |
|---|---|
| Return on Assets | 19.25% |
| Return on Invested Capital | 32.58% |
Valuation & Multiples
| P/E Ratio | 12.36 |
|---|---|
| PEG | -14 |
| Price to Sales | 2.91 |
| Price to Book Ratio | 1.94 |
| Enterprise Value to Revenue | 0.58 |
| Enterprise Value to EBIT | 0.95 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About KemPharm Inc
22 employees
CEO: Travis Mickle KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...